NuView Life Sciences

Binary cancer diagnostics and theranostics,
improving patient outcomes and reducing healthcare costs.

NuView Life Sciences is working to improve the way cancer is diagnosed and treated for our modern healthcare system.

NuView Life Sciences is creating binary cancer diagnostics and Theranostics to improve patient outcomes and reducing healthcare costs.

Led by a multi-disciplinary team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView Life Sciences is poised to change how we look for and respond to cancer.


NuView Life Sciences’s leading technology, NV-VPAC1TM consists of a series of peptide analogs that target the vasoactive intestinal peptide receptor type 1 (VPAC1). The VPAC1 receptor becomes overexpressed in certain key malignancies including breast, prostate, colon, bladder, and endometrial cancer.

In Vivo Diagnostics

a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer

In Vitro Diagnostics

an in vitro diagnostic kit that may be used for detecting shed prostate and bladder cancer cells in voided urine

Theranostics Applications

NuView is preparing to expand its portfolio for Theranostics applications using the NV-VPAC1TM peptide analog…

From the Press


Jay Bishoff, MD, joins The Smith Institute for Urology

Building on a track record of 30 years of innovation in urological surgery and improved outcomes, Jay Bishoff, MD, joins The Smith Institute for Urology…
Press Releases

Oncology Firm Develops Test for Potential Pediatric Cancers Diagnoses

Modern cancer diagnosis tests and treatments are based on what works for adults. A new technology, NV-VPAC1(™), may help doctors better and more accurately diagnose…

Delfi Diagnostics reels in $100M for blood-based cancer test

Last updated: Jan. 14, 2021 By Meg Bryant Liquid biopsy startup Delfi Diagnostics Inc. scooped up $100 million in a series A round led by…

Get Answers From the National Cancer Institute

Information specialists at NCI’s Cancer Information Service (CIS), NCI’s contact center, are available to help answer your cancer-related questions whether you are a patient, family member or friend, health care provider, or researcher. The service is available in English and Spanish.

We are proud to support the American Red Cross